A Phase 1 interventional study of dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) and dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) in Bioequivalence, Fixed Dose Combination Tablets and Healthy Male and Female Subjects, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-13.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 168th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2015, is one of 86 in phase 1, and was the 257th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18–55 · Healthy volunteers
AstraZeneca · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
345 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 47 · Phase 3 122 · Phase 4 28
First in 2001; this study’s year is marked. 15 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 155 across the 280 interventional studies, 2,000 across the 65 observational. Of the 325 that completed or were terminated, 149 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
5 of the studies in Diabetes Mellitus, Type 2 by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723833AstraZenecaA Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | 2026-11-18 |
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions
This is a Phase 1, 2-part, open-label, randomized, 4-period, 4-treatment, crossover study in healthy subjects (males and females of non-childbearing potential)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females must have a negative serum pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-, confirmed at screening by fulfilling 1 of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)
Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)
Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)
Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)
Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
single fixed-combination dose tablets
single fixed-dose combination tablets
single fixed-dose combination tablets
single fixed-dose combination tablets
Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State
To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.
Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.
To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state
Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State
To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state
Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Time to Reach Maximum Plasma Concentration (t Max)
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
This study was conducted at PAREXEL International, Early Phase Clinical Unit Baltimore, United States of America. Subjects were randomized into 4-period, 4-treatment (per study part) crossover (4 sequences containing 4 treatments) in fed and fasted state.
| Milestone | Part 1 | Part 2 |
|---|---|---|
| Started | 40 | 40 |
| Completed | 36 | 39 |
| Not completed | 4 | 1 |
| Withdrew: Positive drug screen at admission | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 |
To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.
| h*ng/mL | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| Dapagliflozin | 236.3 ± 21.06 | 248.6 ± 20.79 | 251.6 ± 21.20 | 258.2 ± 18.35 | 471.9 ± 27.46 | 486.9 ± 26.47 | 504.4 ± 27.22 | 516.6 ± 27.15 |
| Metformin | 5484 ± 24.69 | 5465 ± 27.87 | 4398 ± 29.41 | 4460 ± 29.69 | 8403 ± 27.90 | 8015 ± 31.65 | 7727 ± 30.82 | 7578 ± 35.76 |
To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state
| h*ng/mL | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| Dapagliflozin | 228.1 ± 20.43 | 239.1 ± 21.10 | 243.4 ± 20.93 | 248.8 ± 17.92 | 454.7 ± 27.15 | 472.1 ± 26.72 | 490.9 ± 27.30 | 505.1 ± 26.80 |
| Metformin | 5307 ± 26.54 | 5205 ± 28.59 | 4211 ± 28.71 | 4212 ± 27.22 | 8040 ± 27.82 | 7798 ± 32.77 | 7456 ± 30.57 | 7401 ± 34.75 |
To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state
| ng/mL | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| Dapagliflozin | 39.69 ± 26.42 | 41.33 ± 18.49 | 65.28 ± 25.49 | 67.41 ± 24.95 | 87.48 ± 30.14 | 90.14 ± 32.09 | 125.6 ± 30.77 | 132.7 ± 28.31 |
| Metformin | 510.2 ± 22.23 | 503.4 ± 22.16 | 563.2 ± 30.27 | 573.9 ± 28.55 | 982.6 ± 28.11 | 975.5 ± 27.89 | 1016 ± 35.36 | 998.5 ± 36.05 |
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
| Hour | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| Dapagliflozin | 2.50 (1.00 to 4.00) | 3.00 (1.00 to 4.00) | 1.00 (0.50 to 2.98) | 1.00 (0.48 to 2.92) | 2.00 (0.98 to 4.00) | 2.00 (0.98 to 4.00) | 1.00 (0.50 to 1.98) | 1.00 (0.48 to 3.00) |
| Metformin | 6.00 (4.00 to 11.95) | 6.00 (3.98 to 12.03) | 4.00 (2.00 to 6.00) | 4.00 (2.00 to 6.03) | 4.00 (3.98 to 7.98) | 4.00 (3.98 to 6.02) | 4.00 (1.00 to 6.00) | 4.00 (1.98 to 6.00) |
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
| Hour (h) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| Dapagliflozin | 14.01 ± 6.747 | 14.65 ± 7.245 | 13.73 ± 6.203 | 16.55 ± 8.260 | 14.88 ± 6.272 | 14.42 ± 5.778 | 14.72 ± 5.641 | 15.11 ± 5.998 |
| Metformin | 13.48 ± 7.873 | 12.87 ± 6.587 | 11.91 ± 7.351 | 13.52 ± 8.760 | 14.18 ± 7.718 | 13.74 ± 6.984 | 14.38 ± 8.241 | 15.94 ± 9.671 |
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
| L/h | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| Dapagliflozin | 421.3 ± 194.2 | 424.4 ± 217.3 | 412.7 ± 220.5 | 454.6 ± 202.6 | 476.5 ± 224 | 433.3 ± 196.1 | 441.7 ± 191.7 | 421.4 ± 163.1 |
| Metformin | 2030 ± 1407 | 2133 ± 1891 | 2104 ± 1309 | 2803 ± 2066 | 3357 ± 2549 | 3324 ± 2713 | 3635 ± 2648 | 3212 ± 2079 |
To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.
| L | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| Dapagliflozin | 21.62 ± 4.617 | 20.55 ± 4.506 | 20.32 ± 4.503 | 19.68 ± 3.650 | 21.93 ± 5.747 | 21.22 ± 5.585 | 20.49 ± 5.138 | 20.00 ± 4.974 |
| Metformin | 93.78 ± 22.71 | 94.89 ± 26.81 | 118.1 ± 32.16 | 116.9 ± 36.62 | 123.5 ± 34.68 | 130.5 ± 39.23 | 134.9 ± 37.59 | 140 ± 50.70 |
Collected over From screening until 72 hours postdose for each treatment period (ie. visit 1 to visit 6).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | — | 0/40 (0%) | 2/40 (5%) |
| Treatment B | — | 0/38 (0%) | 5/38 (13.2%) |
| Treatment C | — | 0/37 (0%) | 1/37 (2.7%) |
| Treatment D | — | 0/36 (0%) | 2/36 (5.6%) |
| Treatment E | — | 0/39 (0%) | 2/39 (5.1%) |
| Treatment F | — | 0/40 (0%) | 4/40 (10%) |
| Treatment G | — | 0/39 (0%) | 4/39 (10.3%) |
| Treatment H | — | 0/39 (0%) | 3/39 (7.7%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Treatment G | Treatment H |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/40 | 3/38 | 0/37 | 1/36 | 2/39 | 0/40 | 0/39 | 1/39 |
| DiarrheaGastrointestinal disorders | 0/40 | 2/38 | 1/37 | 1/36 | 0/39 | 2/40 | 3/39 | 2/39 |
| FatigueGeneral disorders | 1/40 | 0/38 | 0/37 | 0/36 | 0/39 | 2/40 | 1/39 | 0/39 |
| Age, Continuous(Years) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Mean | 35.4 ± 10.38 | 38.1 ± 9.71 | 36.5 ± 10.04 |
| Sex: Female, Male(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Female | 1 | 3 | 4 |
| Male | 39 | 37 | 76 |
Ran from Dec 2015 to primary completion in Apr 2016, 3 months.
Results were first posted in Mar 2018, 1 year 11 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.